Geneva Capital Management LLC Cuts Stock Position in Repligen Co. (NASDAQ:RGEN)

Geneva Capital Management LLC cut its holdings in Repligen Co. (NASDAQ:RGEN) by 2.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 135,585 shares of the biotechnology company’s stock after selling 3,092 shares during the quarter. Geneva Capital Management LLC owned 0.24% of Repligen worth $19,516,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Resources Management Corp CT ADV purchased a new position in Repligen during the third quarter worth $37,000. Quarry LP boosted its stake in Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after buying an additional 239 shares during the period. UMB Bank n.a. boosted its stake in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after buying an additional 110 shares during the period. Global Retirement Partners LLC boosted its stake in Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after buying an additional 129 shares during the period. Finally, GAMMA Investing LLC boosted its stake in Repligen by 15.2% during the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after buying an additional 90 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on RGEN shares. Royal Bank of Canada lifted their price objective on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. StockNews.com downgraded Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. Canaccord Genuity Group lifted their target price on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. lifted their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Finally, Wolfe Research began coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $181.00.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $157.67 on Thursday. The business’s 50 day moving average price is $156.74 and its 200 day moving average price is $148.54. The firm has a market cap of $8.83 billion, a P/E ratio of -309.16, a P/E/G ratio of 4.54 and a beta of 0.99. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $203.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. On average, sell-side analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.